Monitoring To Start As SPC Waiver Nears Finishing Line

A manufacturing waiver to allow EU-based companies to produce generics and biosimilars during the SPC term should be approved imminently. But the European Commission is watching closely to see if the provision is used by industry.

Finish
The SPC Waiver Regulation Is Nearing The Finish Line • Source: Shutterstock

The European Commission is preparing to start monitoring the impact of the planned manufacturing waiver that will allow generics and biosimilars developers to produce products within the term of European supplementary protection certificates (SPCs). Alfonso Calles-Sánchez, administrator within the Commission’s directorate general Grow, told delegates to Medicines for Europe’s 15th Legal Affairs Conference that he anticipated a vote in the plenary of the European Parliament in mid-April as one of the final steps to the waiver being approved.

Noting that the inter-institutional agreement between the European Council, Parliament and Commission unveiled in mid-February this year had permitted stockpiling...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.